Over the last six months, Cresco Labs Inc CRLBF shares have fallen 55.83%.
On Tuesday, the company announced the resignation of its president and co-founder Joe Caltabiano, and shares closed the market session 9.59% lower.
The Cresco Labs Analyst
Cantor Fitzgerald analyst Pablo Zuanic reiterated an Overweight rating on Cresco with a $12 price target.
The Cresco Labs Thesis
Caltabiano’s resignation is part of the “natural progression of co-founders/serial entrepreneurs stepping aside and letting more professional management take the reins,” Zuanic said in a Wednesday note. (See his track record here.)
This will boost the company’s validity in connection to its Origin House and Tryke acquisitions and in supporting its expansion efforts in Illinois and Pennsylvania, the analyst said.
Zuanic named several key factors for Cresco investors to watch this year.
First, the integration of Origin House, which will dilute margins and enable Cresco to widen its distribution footprint across California, the analyst said. It "will also expand capacity to allow for partial backwards integration at OH,” he said.
Second, the company’s entrance into other states through acquisitions or organic expansions.
“Yes, integration risk is part of the story with recent acquisitions (esp OH and Tryke) more than doubling the sales base,” Zuanic said.
Cresco is better-positioned than Curaleaf Holdings Inc CURLF, the analyst said.
Cantor "conservatively [values] Cresco at 5x our sales estimates, in line with our valuation of Curaleaf; this approach yields a 12 mo price of ~$8.70," he said.
CRLBF Price Action
Cresco’s shares were trading 3.67% higher at $4.24 at the time of publication Wednesday.
Photo courtesy of Cresco Labs.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.